Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

The Next Great Biotech Boom Has Arrived

Published

on

the-next-great-biotech-boom-has-arrived

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary

LONDON, March 19, 2024 /PRNewswire/ — The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in “magic mushrooms,” as a “breakthrough therapy” for the treatment of major depressive disorder three times. And the world’s largest clinical trial ever into the use of psilocybin for treating depression at London hospital in what scientists are hailing as a “milestone” in mental health research. Mentioned in today’s commentary includes:  Johnson & Johnson (NYSE: JNJ), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), Atai Life Sciences N.V. (NASDAQ: ATAI), AbbVie Inc. (NYSE: ABBV).

This new frontier in treatment has kickstarted a multi-trillion-dollar industry geared at fixing the brain through therapy.

Johnson and Johnson has gone all in on its fastest-growing drug for depression, SPRAVATO, which is the only FDA-approved psychedelic medicine on the market. In its Q4 2023 earnings released in January, JNJ reported a 74.1% increase in sales of SPRAVATO worldwide and views the drug as its next billion-plus product.

And some of the core team members behind the development of the SPRAVATO have now joined a small, but emerging NYSEAmerican-listed company, CYBIN (CYBN, CYBN.NE).

CYBIN has now been granted “Breakthrough Therapy Designation”, and is the first adjunctive psychedelic-based therapy for Major Depressive Disorder (MDD) ever to receive this FDA designation.

Oppenheimer initiated coverage on CYBN last year, saying it was encouraged by the results so far and believed the stock would have room to run further with new results. It has a price target of $4.

H.C.Wainwright & Co. took it further, with a price target of US $10.00 per share, after the recent Small Pharma acquisition.

But with impressive Phase 2 results showing remission after only two doses and a coveted FDA designation, this small company is now poised for much greater attention from investors.

Phase 2: Behind the Breakthrough Therapy Designation

Advertisement

CYBIN is developing differentiated, next-generation therapeutics that hope to offer fast, sustained therapeutic effects that are safe and tolerable, with efficacy in only 1-2 doses and short in-clinic times.

The company is on the leading edge of transformational psychedelic therapeutics, developing novel and proprietary therapeutics to improve clinical outcomes and patients’ mental health and well-being. The emerging biopharmaceutical company already has clinical validation of the novel, proprietary CYB003 molecule, which demonstrates a rapid-acting and robust psychedelic profile at a low dose. And it’s been pounding the patent pavement, too.

In August, CYBIN agreed to acquire Small Pharma Inc in an all-share transaction that creates an international clinical-stage leader in novel psychedelic therapeutics. The companies’ combined portfolios, at closing, will include two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy. The combined portfolio creates the industry’s largest, most advanced, well protected DMT program.

The combined company has the intellectual property strength of 29 patents granted and 158 patents pending in the psychedelic drug development sector. That is the largest portfolio in the industry.

Phase 2 topline efficacy data for the company’s CYBOO3 was one of the biggest drivers of value for CYBIN in the near-term, and the results were even better than expected.

Now that it’s been granted “Breakthrough Therapy Designation”, CYBIN is targeting the potential for its CYB003 to achieve “Best-in-Class Status”, and it’s confident it has a solid shot at this.

In targeting depression, CYBIN’s CYB003 is hoping to offer a lifeline to a chronic illness that victimizes some 280 million people around the world. They are also targeting what is now recognized as the leading cause of disability in the world, which costs the global economy an estimated $1 trillion in lost productivity annually.

Nowhere But Up: The Next Near-Term Catalysts

CYBIN plans to initiate its Phase 3 study of CYBOO3 in MDD in the middle of this year, with the Phase 2 study of CYB004 in Generalized Anxiety Disorder (GAD) launched on March 15.

For the Phase 2 proof-of-concept study of CYB004, CYBIN is using its proprietary DMT molecule, which was developed for the treatment of GAD, following the FDA’s clearance of its new drug application in January.

Advertisement

“We are building on foundational investigative work from our Phase 2a trial of intravenous SPL026 (DMT) which showed preliminary evidence of effectiveness treating anxiety with rapid onset of antidepressant effects and reduction in anxiety scores,” Drysdale said in a press release.

“The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses,” according to Johns Hopkins Center for Psychedelic and Consciousness Research.   This is a space where proprietary IP is absolutely essential, and Cybin now has 29 patents granted and 158 patents pending.

CYBIN (CYBN, CYBN.NE) is a clear leader in the biotech race for an alternative to the antidepressant empire, and now it has breakthrough therapy status, and is the first adjunctive therapy known to achieve this for massive depressive disorder.

Big Pharma is Racing for a Piece of the Pie

Johnson & Johnson (JNJ) is a global leader in healthcare, with a diverse portfolio that spans pharmaceuticals, medical devices, and consumer health products. Within this vast array, Janssen, its pharmaceutical branch, has made significant strides in mental health with esketamine, marketed as Spravato. This nasal spray, a derivative of the anesthetic ketamine, represents a significant breakthrough, gaining FDA approval for use in treatment-resistant depression. The approval of Spravato underscores J&J’s commitment to addressing complex mental health challenges.

AbbVie (ABBV) emerged as a standalone biopharmaceutical entity following its split from Abbott Laboratories in 2013. Focused on discovering treatments for a wide range of diseases, including rheumatoid arthritis and various cancers, AbbVie’s acquisition of Allergan expanded its reach into the burgeoning field of psychedelics for mental health. Allergan, known for its pioneering work in this area, has enriched AbbVie’s pipeline with potential psychedelic-based therapies.

Atai Life Sciences (ATAI) is at the forefront of transforming mental health care, prioritizing the development of treatments for mental health disorders. Atai’s innovative strategy encompasses a wide array of compounds, including psychedelics. The company’s collaborative approach, partnering with leading firms to accelerate the development of groundbreaking therapies, exemplifies its commitment to pioneering advancements in mental health treatment.

Compass Pathways (CMPS) is pioneering the therapeutic use of psilocybin, focusing its research efforts on addressing treatment-resistant depression. The company’s clinical trials and research initiatives are part of a larger mission to establish psilocybin therapy as a validated treatment option, highlighting the potential of psychedelics to offer profound therapeutic benefits. Compass’s dedication to rigorous scientific inquiry and ethical research practices positions it as a leader in the psychedelic research community, contributing valuable insights that could reshape mental health care.

MindMed (MNMD) tands as an innovator in the neuro-pharmaceutical industry, delving into the therapeutic potential of psychedelics for treating a range of mental health conditions. MindMed’s exploratory work with substances such as LSD, MDMA, DMT, and psilocybin is driven by a vision to unlock new treatment pathways for conditions like anxiety, depression, and addiction. Recent advancements in MindMed’s research highlight the company’s role in pioneering the use of psychedelics as therapeutic agents, underscoring the potential of these substances to revolutionize mental health care.

 ** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **

Advertisement

PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin, Inc. (“Cybin” or “Company”) to conduct investor awareness advertising and marketing. Cybin paid the Publisher two hundred and fifty thousand US dollars to produce and disseminate one article profiling the Company over a period of one week. This compensation should be viewed as a major conflict with our ability to be unbiased. 

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Cybin) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s drug pipeline, the reported scheduled release and commercialization of the Company’s drug pipeline, the ability to acquire customers and partners for the Company’s drug pipeline, and the projected growth and profit margins of the Company’s core product offerings.  Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the development and launch of the Company’s drug pipeline, competition, market saturation, market conditions, uncertain regulatory review, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

DISCLAIMER:  GlobalInvestmentDaily.com is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein.  The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Advertisement

Contact Information:

Media Contact e-mail:  editor@financialnewsmedia.com  U.S. Phone: +1(954)345-0611

View original content:https://www.prnewswire.co.uk/news-releases/the-next-great-biotech-boom-has-arrived-302092284.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Multi-Use Bioreactor Market in Pharmaceuticals and Research Institutions to Hit USD 12.26 Billion by 2029, Growing 9.7% Annually | Valuates Reports

Published

on

multi-use-bioreactor-market-in-pharmaceuticals-and-research-institutions-to-hit-usd-1226-billion-by-2029,-growing-9.7%-annually-|-valuates-reports

BANGALORE, India, March 13, 2025 /PRNewswire/ — Multi Use Bioreactor Market is Segmented by Type (Manual, Automatic, Semi-Automatic), by Application (Pharmaceuticals, Scientific Research Institution).

According to new survey, Global Multi Use Bioreactor Market is projected to reach USD.

12260 Million in 2029, increasing from USD 6415 Million in 2022, with a CAGR of 9.7% during the period of 2023 to 2029.

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market

Major Factors Driving the Growth of Multi Use Bioreactor Market:

The multi-use bioreactor market is experiencing sustained growth, driven by advancements in biopharmaceutical production, automation, and process optimization. These systems play a vital role in scaling up biologics manufacturing while maintaining cost efficiency and regulatory compliance. Market players are investing in next-generation bioreactor technologies to enhance productivity and meet evolving industry demands.

The integration of artificial intelligence, real-time monitoring, and hybrid bioprocessing solutions is transforming biomanufacturing practices. As personalized medicine and cell-based therapies gain traction, the demand for flexible and high-performance bioreactors is expected to rise. The continuous expansion of global bioprocessing infrastructure reinforces the market’s long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors.

Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-37Q12337/global-multi-use-bioreactor

TRENDS INFLUENCING THE GROWTH OF THE MULTI USE BIOREACTOR MARKET:

Semi-automatic bioreactors play a crucial role in biopharmaceutical research and industrial fermentation processes by offering a balance between manual control and automation. These systems enable users to adjust key parameters such as temperature, pH, and oxygen levels while leveraging automated controls for consistency. The flexibility of semi-automatic bioreactors makes them ideal for academic institutions, pilot-scale production, and laboratories requiring cost-effective solutions. Their ability to accommodate a wide range of microbial and cell culture processes attracts pharmaceutical companies looking for adaptable production methods. The increasing demand for customized bioproduction, including cell therapy and regenerative medicine, further propels the adoption of semi-automatic bioreactors. These factors drive market growth and expand bioprocessing capabilities globally.

Advertisement

Automatic bioreactors are revolutionizing large-scale biomanufacturing by integrating advanced sensors, AI-driven monitoring, and real-time data analytics. These systems optimize fermentation and cell culture processes, reducing human intervention while ensuring precision and reproducibility. The pharmaceutical industry heavily relies on automatic bioreactors for monoclonal antibody production, vaccine development, and protein synthesis. Their ability to maintain sterile conditions and minimize contamination risks makes them indispensable for biologics manufacturing. The growing trend of continuous bioprocessing and process intensification has further increased demand for automatic bioreactors, enabling high-throughput production. Additionally, biopharma firms are investing in these systems to enhance scalability, reduce operational costs, and streamline regulatory compliance, fueling the expansion of the multi-use bioreactor market.

The pharmaceutical industry is a major driver of the multi-use bioreactor market, as bioreactors are essential for drug discovery, development, and commercial-scale manufacturing. Biopharmaceutical companies use these systems for cell culture applications, vaccine production, and biosimilar development. With the rise of personalized medicine and gene therapy, pharmaceutical firms are shifting toward modular and flexible bioreactor systems to meet evolving production demands. Regulatory agencies emphasize compliance with Good Manufacturing Practices (GMP), encouraging the adoption of high-quality multi-use bioreactors. Additionally, the rapid response to emerging diseases, such as COVID-19, has accelerated investments in bioreactor technology for vaccine research and development. This increasing reliance on bioreactors for pharmaceutical applications significantly contributes to market growth.

The growing prevalence of chronic diseases and the rise of biologics have fueled demand for biopharmaceuticals, driving the need for efficient multi-use bioreactors. As monoclonal antibodies, gene therapies, and biosimilars gain prominence, manufacturers require scalable bioprocessing solutions. Multi-use bioreactors allow efficient production while ensuring consistency and regulatory compliance. Their ability to support various cell lines and microbial cultures enhances flexibility in drug development. This surge in biologics manufacturing directly contributes to market expansion.

Although single-use bioreactors are gaining traction, multi-use bioreactors remain crucial due to their cost efficiency in large-scale production. Many facilities adopt hybrid systems combining single-use and stainless-steel bioreactors to maximize flexibility. Hybrid approaches allow manufacturers to balance cost savings with operational efficiency, reducing turnaround time while maintaining sterility. This transition toward mixed-use systems supports sustainable biomanufacturing and meets evolving industry needs.

The rise of personalized therapies, including CAR-T cell therapies and regenerative medicine, has necessitated adaptable bioprocessing solutions. Multi-use bioreactors support customized production of small-batch biologics tailored to individual patient needs. Their scalability and versatility make them ideal for emerging cell-based therapies. As precision medicine gains momentum, demand for bioreactors catering to specialized manufacturing continues to grow.

While single-use systems dominate small-scale applications, multi-use bioreactors remain cost-effective for high-volume biomanufacturing. Their ability to process large batches of biologics reduces per-unit costs, making them economically viable for commercial production. Established pharmaceutical companies leverage multi-use systems for blockbuster drug manufacturing, ensuring long-term cost savings. This economic advantage reinforces their continued market demand.

Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-37Q12337&lic=single-user

MULTI USE BIOREACTOR MARKET SHARE

North America dominates the market due to the presence of leading biopharma companies, a robust research ecosystem, and significant government funding. Europe follows closely, with stringent regulatory standards and strong biomanufacturing capabilities.

Key Companies:

Advertisement
  • Sartorius
  • Thermo Fisher Scientific Inc
  • General Electric
  • Eppendorf
  • Merck KGaA
  • Pall Corporation
  • ZETA
  • Pierre Guerin
  • Praj Hipurity Systems Limited
  • Bioengineering AG
  • Infors
  • SOLARIS BIOTECHNOLOGY srl
  • Bbi-biotech
  • PBS Biotech;Inc.
  • GEA Group Aktiengesellschaft
  • CerCell A/S

Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!

–          Perfusion Bioreactor market was valued at USD 703.66 Million in 2024 and is anticipated to reach USD 1,153.63 Million by 2031, witnessing a CAGR of 7.19% during the forecast period 2025-2031.
–          Lab Scale Bioreactor market was valued at USD 2369 Million in 2023 and is anticipated to reach USD 4337.5 Million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
–          Single-Use Bioreactors (SUB) Market was valued at USD 220 Million in the year 2024 and is projected to reach a revised size of USD 275 Million by 2031, growing at a CAGR of 3.3% during the forecast period.
–          Bioreactors Market
–          Pharmaceutical Fermentation Bioreactor market is projected to grow from USD 6256 Million in 2024 to USD 11080 Million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.0% during the forecast period.
–          Bioreactors and Fermentors Market
–          Cell Culture Bioreactors Market
–          Bubble Column Bioreactor Market
–          Membrane Bioreactor Systems market was valued at USD 3307.4 Million in 2023 and is anticipated to reach USD 4996.5 Million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
–          Fixed Bed Bioreactors Market
–          Micro Bioreactors Market revenue was USD 133.9 Million in 2022 and is forecast to a readjusted size of USD 246.5 Million by 2029 with a CAGR of 9.0% during the forecast period (2023-2029).

DISCOVER OUR VISION: VISIT ABOUT US!

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.

GET A FREE QUOTE

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335

Advertisement

Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753

https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish

https://www.facebook.com/valuatesjapanese

https://valuatesreportspanish.blogspot.com/

https://valuateskorean.blogspot.com/

https://valuatesgerman.blogspot.com/

https://valuatesreportjapanese.blogspot.com/
 

Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/multi-use-bioreactor-market-in-pharmaceuticals-and-research-institutions-to-hit-usd-12-26-billion-by-2029–growing-9-7-annually–valuates-reports-302401344.html

Continue Reading

Fintech PR

Transactions for persons discharging managerial responsibilities

Published

on

transactions-for-persons-discharging-managerial-responsibilities

Company announcement No. 578, 2025

CEO Jörg Brinkmann have purchased shares in H+H International A/S

COPENHAGEN, Denmark, March 13, 2025 /PRNewswire/ — H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them.

 

 

 

1.

 

                                   

                                   

Advertisement

Details of the person discharging managerial responsibilities/person closely associated  

                                   

                                   

                                   

a)

                                   

                                   

                                   

Name

                                   

Advertisement

 

                                   

                                   

                                   

Jörg Brinkmann

                                   

                                               

 

 

2.

Advertisement

 

                                   

                                   

Reason for the notification

                                   

                                   

                                   

a)

                                   

                                   

Advertisement

                                   

Position/status

                                   

 

                                   

                                   

                                   

CEO

 

                                   

Advertisement

                                               

                                   

                                   

b)

                                   

                                   

                                   

Initial notification/Amendment

                                   

                                   

Advertisement

                                   

Initial notification

                                   

                                               

 

 

3.

 

                                   

                                   

Advertisement

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

                                   

                                   

                                   

a)

                                   

                                   

                                   

Name

                                   

Advertisement

                                   

                                   

H+H International A/S

                                   

                                               

                                   

                                   

b)

                                   

                                   

Advertisement

                                   

LEI

                                   

                                   

                                   

LEI:  3800GJODT6FV8QM841

                                   

                                               

 

 

Advertisement

4.

 

                                   

                                   

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

                                   

                                   

                                   

a)

                                   

Advertisement

                                   

                                   

Description of the financial instrument, type of instrument
                                     

                                   

 

                                   

Identification code

                                   

 

                                   

Advertisement

                                   

                                   

Shares

                                   

 

                                   

DK0015202451

                                   

                                               

                                   

Advertisement

                                   

b)

                                   

                                   

                                   

Nature of the transaction

                                   

                                   

                                   

Purchase

Advertisement

                                   

                                               

                                   

                                   

c)

                                   

                                   

                                   

Price(s) and volume(s)

                                   

Advertisement

 

                                   

Price(s)           

                                                                

Volume(s)

 

DKK 110 per share                                                

2,000

 

                                   

Advertisement

                                   

d)

                                   

                                   

                                   

Aggregated information

                                   

–  Aggregated volume

                                   

–  Aggregated price

Advertisement

                                   

                                   

Aggregated information

                                   

2000 shares

                                   

DKK 220,000

                                   

                                               

                                   

Advertisement

                                   

e)

                                   

                                   

                                   

Date of the transaction(s)

                                   

                                   

                                   

2025-03-10

Advertisement

                                   

                                               

                                   

                                   

f)

                                   

                                   

                                   

Place of transaction(s)

                                   

Advertisement

                                   

                                   

Copenhagen (XCSE)

                                   

                                   

 

 

 

 

 

Advertisement

1.

 

                                   

                                   

Details of the person discharging managerial responsibilities/person closely associated  

                                   

                                   

                                   

a)

                                   

Advertisement

                                   

                                   

Name

                                   

 

                                   

                                   

                                   

Jörg Brinkmann

                                   

Advertisement

                                               

 

 

2.

 

                                   

                                   

Reason for the notification

                                   

                                   

Advertisement

                                   

a)

                                   

                                   

                                   

Position/status

                                   

 

                                   

                                   

Advertisement

                                   

CEO

 

                                   

                                               

                                   

                                   

b)

                                   

                                   

Advertisement

                                   

Initial notification/Amendment

                                   

                                   

                                   

Initial notification

                                   

                                               

 

 

Advertisement

3.

 

                                   

                                   

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

                                   

                                   

                                   

a)

                                   

Advertisement

                                   

                                   

Name

                                   

                                   

                                   

H+H International A/S

                                   

                                               

                                   

Advertisement

                                   

b)

                                   

                                   

                                   

LEI

                                   

                                   

                                   

LEI:  3800GJODT6FV8QM841

Advertisement

                                   

                                               

 

 

4.

 

                                   

                                   

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

                                   

Advertisement

                                   

                                   

a)

                                   

                                   

                                   

Description of the financial instrument, type of instrument
                                     

                                   

 

                                   

Advertisement

Identification code

                                   

 

                                   

                                   

                                   

Shares

                                   

 

                                   

Advertisement

DK0015202451

                                   

                                               

                                   

                                   

b)

                                   

                                   

                                   

Nature of the transaction

Advertisement

                                   

                                   

                                   

Purchase

                                   

                                               

                                   

                                   

c)

                                   

Advertisement

                                   

                                   

Price(s) and volume(s)

                                   

 

                                   

Price(s)                         

                            

                                               

Volume(s)

Advertisement

 

 

DKK 107.6 per share  

2,000

                                   

                                   

d)

                                   

                                   

                                   

Advertisement

Aggregated information

                                   

–  Aggregated volume

                                   

–  Aggregated price

                                   

                                   

                                   

Aggregated information

                                   

Advertisement

2000 shares

                                   

DKK 215,200

                                   

                                               

                                   

                                   

e)

                                   

                                   

Advertisement

                                   

Date of the transaction(s)

                                   

                                   

                                   

2025-03-11

                                   

                                               

                                   

                                   

Advertisement

f)

                                   

                                   

                                   

Place of transaction(s)

                                   

                                   

                                   

Copenhagen (XCSE)

                                   

Advertisement

                                   

 

CONTACT:

For further information please contact:
Niclas Bo Kristensen
Head of Investor Relations & Treasury
+45 24 48 03 67
Nbk@hplush.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h-h-international-a-s/r/transactions-for-persons-discharging-managerial-responsibilities,c4118773

The following files are available for download:

https://mb.cision.com/Main/21438/4118773/3320449.pdf

578 – Transactions for persons discharging managerial responsibilities

View original content:https://www.prnewswire.co.uk/news-releases/transactions-for-persons-discharging-managerial-responsibilities-302401339.html

Advertisement

Continue Reading

Fintech PR

CBC Summit Expands to Europe, Bringing Crypto Banking, Compliance, and Payments Leaders Together in London on March 17, 2026

Published

on

cbc-summit-expands-to-europe,-bringing-crypto-banking,-compliance,-and-payments-leaders-together-in-london-on-march-17,-2026

WASHINGTON, March 13, 2025 /PRNewswire/ — “CBC Summit is excited to announce the expansion of its highly successful US-based event to London on March 17, 2026.

Introduced in 2023, CBC Summit USA has become a must-attend annual gathering in Washington, D.C., for crypto banking, compliance, and payments executives; featuring participation from industry leaders such as Coinbase, Kraken, Ledger, Binance, Elliptic, Stripe, Robinhood, Anchorage Digital Bank, Silicon Valley Bank, Ibanera, and BCB Group.

CBC Summit Europe marks a significant step in expanding the event’s global reach, offering professionals across Europe the opportunity to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.

CBC Summit Europe will provide a platform for over 100 European industry leaders, executives, and government agencies to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.

CBC Summit Europe topics will include:

  • The current state of fintech and crypto banking in the UK and Europe insights into the struggles and solutions to onboarding with crypto friendly banks for fiat on-ramp and off-ramp services in the UK and Europe.
  • Building the new Financial Infrastructure – exchanges and partners are building out their own Layer 2 networks to ease transition to DeFi and map out a new financial infrastructure. What comes next?
  • Navigating AML Challenges in the FCA & MiCA Era – adapting to evolving anti-money laundering regulations.
  • Transforming Global Finance with Stablecoins & Cross-Border Payments – exploring their role in transforming global finance.
  • Financial Crime Trends in Crypto & Fintech – What methods are criminals currently employing, and how is financial crime evolving in crypto?

“The expansion of CBC Summit USA to Europe reflects the growing importance of global collaboration in crypto banking, compliance, and payments” said Joshua Radbod, CEO of CBC Summit. “As the industry continues to evolve, bringing together global leaders from different regulatory environments is crucial for shaping its future.”

Registration & More Information: Registration is now open, and attendees are encouraged to secure their spots in advance. For more details on speakers, sessions, and sponsorship opportunities, visit https://www.cbcsummit.io/europe

About CBC Team: The CBC Team specializes in creating and operating events that address banking, compliance, and payments challenges in emerging industries. For more information, visit CBC Summit.

Media Contact: info@cbcsummit.io

View original content:https://www.prnewswire.co.uk/news-releases/cbc-summit-expands-to-europe-bringing-crypto-banking-compliance-and-payments-leaders-together-in-london-on-march-17-2026-302400124.html

Advertisement
Continue Reading

Trending